Public Health - Use of Opioid Restitution Fund and Training Under the Overdose Response Program
SB594 makes two main changes to Maryland’s public health response to opioid use. First, it updates the training the Maryland Department of Health may provide under the Overdose Response Program so that overdose-response instruction specifically emphasizes restoring breathing, avoiding withdrawal, and providing compassionate post-overdose support and care, in addition to recognizing overdose signs and administering FDA-approved overdose reversal drugs such as naloxone. Second, it revises the rules governing the Opioid Restitution Fund, which holds opioid settlement and judgment revenues, to clarify that spending from the fund must comply with the purposes stated in settlement agreements and judgments and to update the list of authorized uses.
Under the fund provisions, the bill narrows and reorganizes the permitted uses of restitution money. It continues to allow funding for evidence-based prevention, treatment, recovery, and harm-reduction efforts, peer support, recovery support organizations, and evaluation of funded programs, while also expressly adding uses to address racial disparities and socioeconomic disparities in access to prevention, harm reduction, treatment, and recovery support services. It also preserves a pathway for certain pilot programs or demonstration studies if the Opioid Restitution Fund Advisory Council approves them and finds there is emerging evidence or a reasonable basis for funding them.
The bill’s impact on state law is to refine how opioid settlement dollars may be spent and to guide the content of overdose-response training statewide. It affects the Health – General Article provisions governing the Overdose Response Program and the State Finance and Procurement Article provisions governing the Opioid Restitution Fund. State agencies, local partners, nonprofits, and other recipients of opioid settlement funding will need to align their programs and expenditures with the revised statutory priorities and restrictions.
The overall sentiment around SB594 appears strongly favorable and noncontroversial. The recorded votes show unanimous passage in both chambers, with no recorded opposition in any of the listed third-reading votes. The absence of committee transcript material also suggests there was little publicized dispute over the bill’s core policy changes.
Any potential contention is likely limited to the bill’s spending priorities rather than the concept of using opioid settlement funds for opioid abatement. The most notable policy choices are the explicit emphasis on racial and socioeconomic disparities and the requirement that pilot or demonstration projects receive advisory council approval before funding. Those provisions may matter most to agencies and advocates deciding which programs qualify for restitution funding, but the legislative record provided does not show active opposition.
SB594 amends Maryland’s Health – General and State Finance and Procurement laws to change overdose-response training guidance and to tighten and expand the authorized uses of the Opioid Restitution Fund. It directs opioid settlement and judgment revenues toward specified opioid abatement purposes, including evidence-based prevention, treatment, recovery, harm reduction, nonprofit recovery supports, disparity-reduction efforts, and approved pilot or demonstration projects, while requiring consistency with settlement terms and judgments. The bill also affects the Department of Health’s Overdose Response Program by adding more specific training content focused on breathing restoration, withdrawal avoidance, and post-overdose care.
The bill appears to have been received positively and passed with unanimous support in the Senate and House votes provided. There is no evidence in the supplied record of organized opposition, divided committee debate, or significant controversy. The legislative tone suggests broad agreement on refining opioid settlement spending and improving overdose-response training.
The main points of potential contention are policy-level choices about how narrowly opioid restitution dollars should be directed and which populations or interventions should receive priority. In particular, the bill expressly elevates funding to address racial and socioeconomic disparities in access to services, and it requires advisory council approval for certain non-evidence-based pilot or demonstration projects. Those choices could be debated by advocates, service providers, and policymakers over allocation of limited settlement funds, but the available voting record shows no recorded opposition.